This article is more than 5 years old. Information may no longer be current.
Seven important updates in immuno-oncology
Click Here to Manage Email Alerts
Healio.com and HemOnc Today provide a compilation of seven important updates in immuno-oncology from the past month.
1. More than half of patients with pancreatic adenocarcinoma showed clinical responses when treated with an investigational multiantigen-specific T-cell therapy. Read more.
2. Abramson Cancer Center at University of Pennsylvania received a $12 million grant from the Mark Foundation for Cancer Research to investigate the complementary potential of radiotherapy and immunotherapy for the treatment of cancer. Read more.
3. Combining radiotherapy and pembrolizumab (Keytruda, Merck) appeared safe and induced promising responses among patients with advanced non-small cell lung cancer, according to results of two phase 2 studies published in JAMA Oncology. Read more.
4. Max S. Topp, MD, head of hematology at University Hospital of Wuerzburg, Germany, spoke with HemOnc Today about results from the ZUMA-1 trial that showed early use of steroids may reduce incidence of severe cytokine release syndrome and neurologic events among patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel (Yescarta, Kite Pharma), an autologous anti-CD19 chimeric antigen receptor T-cell therapy. Early steroid use did not affect response rates. Watch here.
5. Nivolumab (Opdivo, Bristol-Myers Squibb) demonstrated limited activity among patients with untreated brain metastases from clear cell renal cell carcinoma who experienced progression after vascular endothelial growth factor receptor-directed therapy. Read more.
6. Researchers at Icahn School of Medicine at Mount Sinai have developed a novel vaccine that uses immune stimulants to inhibit cancer cell growth among patients with advanced-stage lymphoma. Read more.
7. Heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and prior ibrutinib treatment achieved rapid and durable responses with the investigational CAR T-cell product lisocabtagene maraleucel (JCAR017; Celgene, Juno Therapeutics). Read more.